AGE RELATED MACULAR DEGENERATION (ARMD)
Clinical trials for AGE RELATED MACULAR DEGENERATION (ARMD) explained in plain language.
Never miss a new study
Get alerted when new AGE RELATED MACULAR DEGENERATION (ARMD) trials appear
Sign up with your email to follow new studies for AGE RELATED MACULAR DEGENERATION (ARMD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a daily injection save your sight? new trial for dry AMD
Disease control OngoingThis phase 3 trial tests whether a daily injection of elamipretide can slow vision loss in people with dry age-related macular degeneration (AMD). About 313 adults aged 55 and older with early dry AMD will receive either the drug or a placebo for 96 weeks. The main goal is to see…
Matched conditions: AGE RELATED MACULAR DEGENERATION (ARMD)
Phase: PHASE3 • Sponsor: Stealth BioTherapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Can your diet and habits protect your eyes? new study investigates AMD risk factors
Knowledge-focused OngoingThis study is looking at how genetics, diet, lifestyle, and medications work together to influence the risk of age-related macular degeneration (AMD), a leading cause of vision loss. Researchers will collect blood samples and health information from 1,800 adults in Portugal. The …
Matched conditions: AGE RELATED MACULAR DEGENERATION (ARMD)
Phase: NA • Sponsor: Association for Innovation and Biomedical Research on Light and Image • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC